SMN2 pre-mRNA
Assets acting on this target.
- Class
- SMN2 splicing-modifying antisense oligonucleotide
By indication
Related mechanisms
SMN2 pre-mRNA drugs compared
2 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| NusinersenSpinraza | Biogen, Ionis Pharmaceuticals | antisense | Approved | Approved in Spinal Muscular Atrophy |
| Risdiplam (Evrysdi)Evrysdi | Genentech (Roche Group), Roche | small molecule | Approved | Approved in Spinal Muscular Atrophy |